Kenvue (NYSE:KVUE) Updates FY 2024 Earnings Guidance

Kenvue (NYSE:KVUE) updated its FY 2024 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 1.100-1.200 for the period, compared to the consensus estimate of 1.140. The company issued revenue guidance of $15.6 billion-$15.6 billion, compared to the consensus revenue estimate of $15.7 billion.

Kenvue Trading Down 3.1 %

Shares of NYSE:KVUE opened at $22.50 on Thursday. The company has a 50 day moving average of $22.59 and a 200-day moving average of $20.49. The company has a current ratio of 0.99, a quick ratio of 0.68 and a debt-to-equity ratio of 0.69. The firm has a market cap of $43.09 billion, a P/E ratio of 38.79, a P/E/G ratio of 3.01 and a beta of 1.36. Kenvue has a twelve month low of $17.67 and a twelve month high of $23.57.

Kenvue (NYSE:KVUE) last released its earnings results on Tuesday, August 6th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.04. Kenvue had a return on equity of 21.80% and a net margin of 7.23%. The firm had revenue of $4 billion during the quarter, compared to the consensus estimate of $3.93 billion. During the same period in the prior year, the firm posted $0.32 earnings per share. The firm’s revenue for the quarter was down .3% compared to the same quarter last year. As a group, analysts anticipate that Kenvue will post 1.08 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th will be issued a $0.205 dividend. The ex-dividend date is Wednesday, November 13th. This represents a $0.82 annualized dividend and a dividend yield of 3.64%. Kenvue’s dividend payout ratio (DPR) is 141.38%.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on KVUE. Deutsche Bank Aktiengesellschaft lifted their target price on Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Citigroup dropped their target price on shares of Kenvue from $21.00 to $20.00 and set a “neutral” rating on the stock in a report on Wednesday, July 10th. Bank of America increased their target price on shares of Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, October 22nd. Royal Bank of Canada lowered shares of Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price target on the stock. in a research report on Tuesday, September 24th. Finally, JPMorgan Chase & Co. raised their price objective on Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $22.64.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.